Filing Analysis
This is an amendment to a previous 8-K filing regarding the appointment of Dr. Daniel Gilmer to the Board of Directors. The amendment specifically discloses his assignment to the Nominating and Corporate Governance Committee.
📋 Key Facts
- Dr. Daniel Gilmer was appointed to the Board effective April 24, 2026.
- On June 24, 2026, Dr. Gilmer was assigned to the Nominating and Corporate Governance Committee.
- Compensation for committee service will follow the non-employee director compensation program described in the proxy statement dated April 27, 2026.
- The cash retainer for his committee service is $5,000, pro-rated based on the effective date.
Armata Pharmaceuticals issued a press release regarding Phase 2 Tailwind study results for inhaled AP-PA02 in non-cystic fibrosis bronchiectasis subjects. The company also updated its corporate presentation.
📋 Key Facts
- Announced results from the Phase 2 'Tailwind' study of inhaled AP-PA02.
- Study focus: Non-cystic fibrosis bronchiectasis subjects with chronic Pseudomonas aeruginosa infection.
- Updated corporate presentation dated December 19, 2024, replacing the November 15, 2024 version.
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Armata Pharmaceuticals announced the departure of its Chief Medical Officer, Dr. Mina Pastagia, effective November 13, 2024. The company has entered into a separation agreement providing twelve months of base salary in exchange for a general release of claims.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in a clinical-stage biotech company can signal internal shifts or delays in clinical development pipelines.
📋 Key Facts
- Dr. Mina Pastagia's employment as Chief Medical Officer concluded on November 13, 2024.
- The Company entered into a Separation and Release Agreement with Dr. Pastagia on December 2, 2024.
- Under the agreement, Dr. Pastagia is entitled to continued base salary payments for twelve (12) months following her termination date.
- Payments are contingent upon non-revocation of and compliance with the Separation Agreement.
Armata Pharmaceuticals has amended its existing credit agreements with Innoviva Strategic Opportunities LLC to extend the maturity dates of both its Credit Agreement and Convertible Credit Agreement to January 10, 2026. Additionally, the company announced the termination of its Chief Medical Officer, Dr. Mina Pastagia, and the hiring of new finance and regulatory leadership.
🚩 Red Flags
- Termination of the Chief Medical Officer (CMO) during a critical transition toward Phase 3 trials.
- Significant cash outflow required for CMO separation package (12 months of base salary).
📋 Key Facts
- Extended maturity date for the Credit Agreement and Convertible Credit Agreement to January 10, 2026.
- Termination of Chief Medical Officer Mina Pastagia, effective November 13, 2024.
- Dr. Pastagia is eligible for 12 months of continued base salary in exchange for a general release of claims.
- Hired David House (Finance) and Arwa Shurrab (Regulatory Strategy/Operations) to support upcoming Phase 3 clinical trials.
- Company is preparing for two potential Phase 3 licensure-supporting trials in 2025.
Armata Pharmaceuticals, Inc. announced its financial results for the three and nine months ended September 30, 2024. The filing serves as a formal notification that earnings data has been furnished via press release.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2024.
- Announcement date: November 13, 2024.
- Financial results were provided via Exhibit 99.1 (Press Release).
Armata Pharmaceuticals announced the full enrollment of its Phase 1b/2a diSArm study for intravenous AP-SA02, targeting Staphylococcus aureus bacteremia. This is a clinical trial milestone reported via Regulation FD disclosure.
📋 Key Facts
- Achieved full enrollment in the Phase 1b/2a diSArm study.
- The study evaluates intravenous AP-SA02 as a treatment for Staphylococcus aureus bacteremia.
- Announcement made on November 12, 2024.
Armata Pharmaceuticals, Inc. announced the departure of its Vice President and Corporate Controller, Richard Rychlik, effective September 30, 2024. The company entered into a separation agreement providing continued salary and COBRA benefits through year-end.
🚩 Red Flags
- Sudden departure of a key finance officer (Corporate Controller) can sometimes precede internal control reviews or reporting delays, though no such issues were explicitly stated here.
📋 Key Facts
- Richard Rychlik (VP, Corporate Controller) departed the company on September 30, 2024.
- The departure was via a Confidential Separation and Release Agreement.
- Separation terms include continued base salary and subsidized COBRA premiums through December 31, 2024.
- Departure is subject to compliance with the separation agreement.
Armata Pharmaceuticals, Inc. announced that Richard Rychlik, the Vice President and Corporate Controller, will conclude his employment effective September 30, 2024. The terms of his separation agreement are currently being negotiated.
🚩 Red Flags
- Departure of a key financial officer (Corporate Controller) can sometimes precede internal control reviews or restatements, though no such issues were noted in this filing.
📋 Key Facts
- Richard Rychlik is departing from his role as VP, Corporate Controller.
- Departure date: September 30, 2024.
- The company and Mr. Rychlik are currently negotiating the terms of a separation agreement.
Armata Pharmaceuticals issued an 8-K to provide Regulation FD disclosures regarding a poster presentation for the 2024 Military Health System Research Symposium and updated its corporate presentation. The filing includes a correction noting that enrollment figures in the poster presentation have increased from ~75% to 80%.
📋 Key Facts
- Company is presenting at the 2024 Military Health System Research Symposium (August 26-29, 2024).
- Enrollment figures in the poster presentation were updated from ~75% to 80%.
- Completion of current enrollment/study phase is projected for Q4 2024.
- The company updated its official Corporate Presentation on August 26, 2024.
Armata Pharmaceuticals, Inc. announced the appointment of David House as Senior Vice President, Finance and Principal Financial Officer, effective August 16, 2024. Mr. House will succeed Richard Rychlik in the PFO role, though Mr. Rychlik will remain with the company as VP, Corporate Controller.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- David House appointed as Senior Vice President, Finance and Principal Financial Officer effective August 16, 2024.
- Base salary of $350,000 per annum with a target annual bonus of 40%.
- Equity grant: Option to purchase 75,000 shares of common stock under the 2016 Equity Incentive Plan, vesting over four years.
- Mr. House previously served as Corporate Controller and VP of Accounting at ZO Skin Health, Inc.
Armata Pharmaceuticals, Inc. announced its financial results for the three and six months ended June 30, 2024. The filing serves as a formal notice that earnings data has been furnished via press release.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Three and six months ended June 30, 2024
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Armata Pharmaceuticals, Inc. filed an 8-K to announce an amendment to the employment agreement of Chief Medical Officer Dr. Mina Pastagia. The amendment formalizes her role and updates compensation terms including base salary, bonus eligibility, and future equity grant intentions.
🚩 Red Flags
- None identified; this is a standard administrative update to executive compensation terms.
📋 Key Facts
- Amendment to Dr. Mina Pastagia's Employment Agreement dated July 22, 2024.
- Dr. Pastagia has served as Chief Medical Officer since January 1, 2023.
- Base salary is confirmed at $456,800 per annum.
- Target annual bonus opportunity set at 50% of base salary starting fiscal year 2024.
- Eligibility for additional equity grants under the 2016 Equity Incentive Plan commencing in 2025, with an intended fair value of $300,000.
Armata Pharmaceuticals, Inc. reported the results of its Annual Meeting of Shareholders held on June 12, 2024. The meeting included the election of seven board members and the ratification of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Seven directors were elected to one-year terms expiring in 2025: Deborah L. Birx, Jules Haimovitz, Odysseas D. Kostas, Robin C. Kramer, Joseph M. Patti, Todd C. Peterson, and Sarah Schlesinger.
- Shareholders approved the compensation of named executive officers on a non-binding advisory basis (Say-on-Pay).
- Shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.
Armata Pharmaceuticals, Inc. announced its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that earnings data was furnished via press release.
📋 Key Facts
- Report date: May 7, 2024
- Reporting period: Three months ended March 31, 2024
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
- Financial results were released via press release (Exhibit 99.1).
Armata Pharmaceuticals, Inc. has announced the date for its 2024 annual meeting of stockholders and established deadlines for stockholder proposals and director nominations.
📋 Key Facts
- Annual Meeting Date: June 12, 2024, at 8:30 a.m. PT via virtual web service.
- Record Date for voting rights: Close of business on April 19, 2024.
- Rule 14a-8 Deadline (Stockholder proposals): April 1, 2024, at 5:00 p.m. ET.
- Advance Notice Bylaws Provision Deadline (Director nominations/proposals): April 1, 2024, at 5:00 p.m. ET.
Armata Pharmaceuticals announced its financial results for the three months and full fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's quarterly and annual earnings performance.
📋 Key Facts
- Reporting period: Three months and full fiscal year ended December 31, 2023.
- Announcement date: March 21, 2024.
- The filing includes the results of operations and financial condition as per Item 2.02.
Armata Pharmaceuticals entered into a $35 million secured term loan facility with Innoviva Strategic Opportunities LLC, a subsidiary of its principal shareholder. The loan carries a high interest rate of 14% per annum and matures on June 4, 2025.
🚩 Red Flags
- High-interest debt (14% per annum) suggests significant cost of capital and potential liquidity pressure.
- Related-party transaction: The lender is a subsidiary of the company's principal shareholder.
- Short maturity: The loan matures in approximately 15 months (June 2025), creating near-term refinancing risk.
- Asset-backed: The loan is secured by substantially all of the Company's assets.
📋 Key Facts
- Entered into a Credit Agreement on March 4, 2024.
- Loan amount: $35 million secured term loan facility.
- Interest rate: 14.0% per annum.
- Maturity date: June 4, 2025.
- Lender is Innoviva Strategic Opportunities LLC, a subsidiary of the Company's principal shareholder.
- Loan is secured by substantially all assets of the Company and its domestic subsidiaries.